 Acasti Pharma Inc NASDAQ:ACST CVE:ACST FRA:A1PA, which is currently going through a review process aimed at enhancing shareholder value, posted Tuesday its fiscal third-quarter results to end-December last year. In the statement, the biopharma said it believes it has enough cash to fund it through this process, or at least the next 12 months. 